Shionogi & Co., Ltd.
1-8, Doshomachi 3-Chome
Chuo-ku
Osaka
541-0045
Tel: 81-0-6-6202-2161
Fax: 81-0-6-6229-9596
Website: http://www.shionogi.co.jp/
117 articles about Shionogi & Co., Ltd.
-
PureTech Founded Entity Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx ® for Pediatric ADHD Patients in Japan
2/27/2024
PureTech Health plc, a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, noted that its Founded Entity Akili, Inc. announced that its Japanese partner Shionogi & Co. Ltd has submitted Akili’s digital therapeutic SDT-001 for marketing approval with the Ministry of Health, Labor, and Welfare.
-
Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan
2/26/2024
Akili Announces Positive Results from Shionogi’s Phase 3 Clinical Trial of Localized Version of Akili’s EndeavorRx® for Pediatric ADHD Patients in Japan.
-
Apnimed Announces Launch of Joint Venture with Shionogi to Develop Novel Pharmacologic Therapies for Obstructive Sleep Apnea and other Sleep Disorders
11/1/2023
Apnimed, Inc. announced a new joint venture with Shionogi & Co., Ltd., a leading global research-driven pharmaceutical company based in Japan, to develop novel pharmacologic therapies to treat obstructive sleep apnea and other sleep disorders.
-
F2G and Shionogi Present Full Data Set from Pivotal Phase 2b Study at Trends in Medical Mycology (TIMM) 2023 Demonstrating Positive Therapeutic Responses in Patients with Invasive Fungal Infections Treated with Oral Olorofim
10/21/2023
F2G Ltd. and Shionogi & Co., Ltd., announced full results from the pivotal Phase 2b open-label study of olorofim in patients with proven invasive fungal infections or probable pulmonary invasive aspergillosis and limited or no treatment options.
-
IDWeek 2023: Shionogi Presents New Real-World Evidence Demonstrating Effectiveness of Earlier Treatment with Fetroja® (cefiderocol) in Appropriate Patients
10/11/2023
Shionogi & Co., Ltd. announced that it will present real-world evidence suggesting treatment with Fetroja® is effective in treating Gram-negative infections and that appropriate patients who received Fetroja earlier had lower in-hospital all-cause mortality than those receiving it later.1 The data are being presented at IDWeek 2023, which is taking place in Boston, October 11-15.
-
Zatolmilast, an Investigational Treatment for Fragile X Syndrome, Receives Rare Pediatric Disease Designation from the U.S. FDA
9/27/2023
Shionogi & Co., Ltd. announced the U.S. Food and Drug Administration (FDA) has granted Tetra Therapeutics Inc. (hereafter "Tetra"), a Shionogi Group Company, Rare Pediatric Disease Designation for zatolmilast (BPN14770), an investigational treatment being studied for Fragile X syndrome (FXS), a leading cause of inherited intellectual disability and autism.
-
Shionogi Presents New Ensitrelvir Clinical and Real-World Data Reinforcing Potential Across COVID-19 Populations at ESWI 2023
9/18/2023
Shionogi & Co., Ltd. will present two late-breaking posters at the European Scientific Working Group on Influenza and other Respiratory Viruses’ (ESWI), 9th Influenza Conference.
-
Critical agreement paves way for new model to accelerate access to important antibiotics for serious bacterial infections
9/12/2023
A new agreement is poised to accelerate antibiotic access for tens of thousands of patients in regions with the highest rates of antimicrobial resistance.
-
Shionogi Further Extends Infectious Disease Innovation Platform with Planned Acquisition of Qpex Biopharma, Inc.
6/26/2023
Shionogi & Co., Ltd. announced that Shionogi Inc., a New Jersey-based subsidiary of Shionogi, has entered into a definitive agreement pursuant to which Shionogi Inc. will acquire Qpex Biopharma, Inc.
-
The acquisition of the privately-held company will bring its novel, investigational beta-lactamase inhibitors and other antimicrobials into the Japanese pharma’s pipeline.
-
Shionogi Enrolls the First Participant in Japan in its Global Phase 3 Trial of Ensitrelvir for the Prevention of Symptomatic SARS-CoV-2 Infection
6/9/2023
Shionogi & Co., Ltd. today announced the first participant has been enrolled in Japan in its global Phase 3 study, Stopping COVID-19 pRogression with early Protease InhibitOr treatment – Post Exposure Prophylaxis (SCORPIO-PEP).
-
Shionogi Advances Ensitrelvir Fumaric Acid COVID-19 Antiviral Clinical Program
2/15/2023
Shionogi & Co., Ltd. announced progress on its comprehensive clinical development program for the novel COVID-19 oral antiviral ensitrelvir.
-
Shionogi, GARDP and CHAI Announce Landmark License and Collaboration Agreements to Treat Bacterial Infections by Expanding Access to Cefiderocol in 135 Countries
6/15/2022
Shionogi & Co., Ltd. and the Global Antibiotic Research and Development Partnership have announced the execution of a license and technology transfer agreement and, with the Clinton Health Access Initiative, a collaboration agreement that aim to significantly transform the landscape of access to antibiotics for countries around the world.
-
With COVID-19 still very much a threat to the public, researchers are working on developing new treatments. Read on for more updates.
-
NIBIOHN, Shionogi Discover Host Immune-dependent Novel Anti-coronavirus Antibody
2/16/2022
The National Institutes of Biomedical Innovation, Health and Nutrition in partnership with Shionogi & Co. has successfully identified a novel antiviral antibody for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), its variants, and closely associated coronavirus species.
-
This week, Gilead Sciences took a $1.25 billion hit after reaching a settlement with ViiV Healthcare on a patent dispute involving the HIV drug dolutegravir.
-
Shionogi Presents the Results of COVID-19 Therapeutic Agent at ISIRV-WHO Virtual Conference
10/21/2021
Shionogi Presents the Results of COVID-19 Therapeutic Agent at ISIRV-WHO Virtual Conference
-
Shionogi to Present In Vitro and Real-World Data at IDWeek 2021 Demonstrating Activity of FETROJA® (cefiderocol) Against Gram-Negative Pathogens
9/28/2021
Shionogi to Present In Vitro and Real-World Data at IDWeek 2021 Demonstrating Activity of FETROJA ® (cefiderocol) Against Gram-Negative Pathogens
-
ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COVID-19
7/17/2021
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc, with Pfizer Inc. and Shionogi Limited as shareholders, presented positive findings from the CUSTOMIZE trial.
-
ViiV Healthcare presents data from second Dovato (dolutegravir/lamivudine) switch study confirming non-inferior efficacy and no virologic failure versus a broad range of regimens of at least 3 drugs
7/17/2021
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc, with Pfizer Inc. and Shionogi Limited as shareholders, presented 48-week data from the SALSA study at the International AIDS Society Conference 2021, being held virtually 18-21 July.